Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Concurrent Neoadjuvant Chemoradiotherapy Plus Durvalumab (MEDI4736) in Resectable Stage III NSCLC	Potentially Resectable Stage II/IIIa NSCLC	Recruiting	Phase 1 / Phase 2	2026-05-14		NCT03694236

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Yonsei University	213

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Severance Hospital	Seoul	South Korea	6

Clinical trials